John R. Penrod

3.7k total citations
95 papers, 2.4k citations indexed

About

John R. Penrod is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, John R. Penrod has authored 95 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 50 papers in Pulmonary and Respiratory Medicine and 26 papers in Economics and Econometrics. Recurrent topics in John R. Penrod's work include Lung Cancer Treatments and Mutations (44 papers), Cancer Immunotherapy and Biomarkers (29 papers) and Health Systems, Economic Evaluations, Quality of Life (22 papers). John R. Penrod is often cited by papers focused on Lung Cancer Treatments and Mutations (44 papers), Cancer Immunotherapy and Biomarkers (29 papers) and Health Systems, Economic Evaluations, Quality of Life (22 papers). John R. Penrod collaborates with scholars based in United States, United Kingdom and Canada. John R. Penrod's co-authors include Lawrence Joseph, Ann E. Clarke, Yvan St‐Pierre, Viviane Adam, Patrick Bélisle, Paul R. Fortin, Bruno Fautrel, Charlotte B. Phillips, Nizar N. Mahomed and Clement B. Sledge and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

John R. Penrod

91 papers receiving 2.4k citations

Peers

John R. Penrod
Lauren P. Wallner United States
Christopher J.D. Wallis Canada
Marta Soares United Kingdom
Bruce Crawford United States
Peter W. Rose United Kingdom
Rachel Waters United Kingdom
Chisato Hamashima Japan
Raj Satkunasivam United States
Christopher Hogan United States
Angela B. Smith United States
Lauren P. Wallner United States
John R. Penrod
Citations per year, relative to John R. Penrod John R. Penrod (= 1×) peers Lauren P. Wallner

Countries citing papers authored by John R. Penrod

Since Specialization
Citations

This map shows the geographic impact of John R. Penrod's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John R. Penrod with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John R. Penrod more than expected).

Fields of papers citing papers by John R. Penrod

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John R. Penrod. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John R. Penrod. The network helps show where John R. Penrod may publish in the future.

Co-authorship network of co-authors of John R. Penrod

This figure shows the co-authorship network connecting the top 25 collaborators of John R. Penrod. A scholar is included among the top collaborators of John R. Penrod based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John R. Penrod. John R. Penrod is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Hatswell, Anthony J., et al.. (2023). Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer. PharmacoEconomics. 42(1). 109–116. 1 indexed citations
4.
Provencio, Mariano, Enric Carcereny, Rafael López Castro, et al.. (2023). Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study. Translational Lung Cancer Research. 12(10). 2113–2128. 7 indexed citations
5.
6.
7.
8.
Shafrin, Jason, Suepattra G. May, Katalin Bognar, et al.. (2021). Measuring the Value Healthy Individuals Place on Generous Insurance Coverage of Severe Diseases: A Stated Preference Survey of Adults Diagnosed With and Without Lung Cancer. Value in Health. 24(6). 855–861. 7 indexed citations
9.
Stenehjem, David D., Solomon J. Lubinga, Komal Gupte-Singh, et al.. (2020). Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non–Small-Cell Lung Cancer in the United States. Clinical Lung Cancer. 22(1). e35–e47. 5 indexed citations
10.
DiBonaventura, Marco, et al.. (2019). <p>Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan</p>. Therapeutics and Clinical Risk Management. Volume 15. 355–366. 18 indexed citations
11.
Cope, Shannon, Rachel Goldgrub, Dieter Ayers, et al.. (2019). Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer. Journal of Comparative Effectiveness Research. 8(10). 733–751. 6 indexed citations
12.
Reck, Martin, Fiona Taylor, John R. Penrod, et al.. (2017). Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study. Journal of Thoracic Oncology. 13(2). 194–204. 79 indexed citations
13.
Panter, Charlotte, et al.. (2017). The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature. Frontiers in Pharmacology. 8. 339–339. 23 indexed citations
14.
15.
Corral, Mitra, John R. Penrod, Ying Zhang, et al.. (2014). New drugs not major cost drivers for lung cancer care. The American Journal of Managed Care. 6(3). 1 indexed citations
16.
Lü, Yang, et al.. (2012). Dynamic cost-effectiveness of oncology drugs.. PubMed. 18(11 Suppl). S249–56. 12 indexed citations
17.
Ghasemi, Hamid, et al.. (2009). Developing Advanced Methods of Assessing Bridge Performance. Public roads. 73(3). 28–35. 7 indexed citations
18.
Panopalis, Pantelis, Michelle Petri, Susan Manzi, et al.. (2007). The systemic lupus erythematosus Tri‐Nation study: Cumulative indirect costs. Arthritis Care & Research. 57(1). 64–70. 52 indexed citations
19.
Vasiliadis, Helen‐Maria, Jean‐Paul Collet, John R. Penrod, Pasquale Ferraro, & Charles Poirier. (2005). A Cost-Effectiveness and Cost-Utility Study of Lung Transplantation. The Journal of Heart and Lung Transplantation. 24(9). 1275–1283. 40 indexed citations
20.
Penrod, John R., et al.. (2003). Surgical placement of two implants in the anterior edentulous mandible – how much time does it take?. Clinical Oral Implants Research. 14(2). 188–192. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lauren P. Wallner Breakdown of academic impact, for papers by Christopher J.D. Wallis Breakdown of academic impact, for papers by Marta Soares Breakdown of academic impact, for papers by Bruce Crawford Breakdown of academic impact, for papers by Peter W. Rose Breakdown of academic impact, for papers by Rachel Waters Breakdown of academic impact, for papers by Chisato Hamashima Breakdown of academic impact, for papers by Raj Satkunasivam Breakdown of academic impact, for papers by Christopher Hogan Breakdown of academic impact, for papers by Angela B. Smith
Rankless by CCL
2026